Aarpik Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 15-06-2024
- Paid Up Capital ₹ 0.20 M
as on 15-06-2024
- Company Age 27 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.44 Cr
as on 15-06-2024
- Revenue %
(FY 2023)
- Profit 188.39%
(FY 2023)
- Ebitda 91.27%
(FY 2023)
- Net Worth 6.49%
(FY 2023)
- Total Assets 6.66%
(FY 2023)
About Aarpik Remedies
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹3.44 Cr.
Archna Jaiswal and Manohar Jaiswal serve as directors at the Company.
- CIN/LLPIN
U24110GJ1997PTC032952
- Company No.
032952
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Sep 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aarpik Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Archna Jaiswal  | Director | 04-Sep-1997 | Current |
| Manohar Jaiswal | Director | 30-Apr-2002 | Current |
Financial Performance of Aarpik Remedies.
Aarpik Remedies Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 188.39% increase in profit. The company's net worth moved up by a moderate rise of 6.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aarpik Remedies?
In 2023, Aarpik Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aarpik Pharmaceuticals Private LimitedActive 29 years 11 monthsArchna Jaiswal and Manohar Jaiswal are mutual person
Totem Biotech Private LimitedActive 21 years 10 monthsArchna Jaiswal and Manohar Jaiswal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 15 Nov 2019 | ₹3.42 Cr | Open |
Bank Of India Creation Date: 14 Oct 2002 | ₹0.20 M | Open |
How Many Employees Work at Aarpik Remedies?
Unlock and access historical data on people associated with Aarpik Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aarpik Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aarpik Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
